Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pravastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 9/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 1.00 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.84 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.55 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.55 |
| ▸ | PGR | P06401 | 1/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pravastatin SCHEMBL1683285 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL13575802 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL13318941 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL13743095 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL13198584 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL14430952 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL23936980 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL14430866 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL2305070 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL967719 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 80730 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144789-A1 | WOUND TREATMENTS AND COMPOSITIONS | CMPD LICENSING, LLC (US) | 2026-05-28 | — | — | US | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| CN-122075699-A | Application of calcium activated chloride channel AN01/TMEM16A in preventing and treating atherosclerosis | — | 2026-05-26 | — | — | CN | claimed |
| US-12636273-B2 | Compositions for pathogenesis-directed therapy and treatments of skin diseases and disorders | YALE UNIVERSITY (US) | 2026-05-26 | — | — | US | claimed |
| EP-4745160-A1 | METHOD FOR TREATING OR PREVENTING CHOLESTEROL-RELATED DISEASES USING PCSK9 INHIBITOR | Salubris (Chengdu) Biotech Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| US-20260124215-A1 | METHODS OF TREATMENT OF INTESTINAL INFECTIONS | THE FRANCIS CRICK INST LIMITED (GB) | 2026-05-07 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-3681481-B1 | COMPOSITIONS FOR PREVENTING AND TREATING HETEROTOPIC OSSIFICATION AND PATHOLOGIC CALCIFICATION | NOSTOPHARMA LLC (US) | 2026-05-06 | — | — | EP | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| EP-4732002-A2 | MOLECULAR SIGNATURES OF LONG-TERM HEPATOCELLULAR CARCINOMA RISK IN NON-ALCOHOLIC FATTY LIVER DISEASE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-04-29 | — | — | EP | claimed |
| US-4933165-A | Coenzyme Q10 with HMG-CoA reductase inhibitors | MERCK & CO., INC. (US) | 1990-06-12 | — | — | US | claimed |
| US-4929437-A | Coenzyme Q10 with HMG-CoA reductase inhibitors | MERCK & CO., INC. (US) | 1990-05-29 | — | — | US | claimed |
| EP-0369263-A2 | Preparations for the topical treatment of skin diseases | F. HOFFMANN-LA ROCHE AG (CH) | 1990-05-23 | — | — | EP | claimed |
| US-4915954-A | Dosage form for delivering a drug at two different rates | ALZA CORPORATION (US) | 1990-04-10 | — | — | US | claimed |
| CN-1036508-A | pharmaceutical preparation with good stability | SQUIBB & SONS INC (US) | 1989-10-25 | — | — | CN | claimed |
| EP-0336298-A1 | Pharmaceutical compositions having good stability | E.R. Squibb & Sons, Inc. (US) | 1989-10-11 | — | — | EP | claimed |
| US-4584389-A | Processes for preparing 6(R)-[2-[8(S)(2,2-dimethylbutyryloxy)-2(S),6(S)-dimethyl-1,2,3,4,4a(S),5,6,7,8,8a(S)-decahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one | MERCK & CO., INC. (US) | 1986-04-22 | — | — | US | claimed |
| EP-0137444-A2 | Processes for preparing 6(R)-[2-[8(S)(2,2-dimethylbutyryloxy)-2(S),6(S)-dimethyl-1,2,3,4,4a(S),5,6,7,8,8a(S)-Decahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one | MERCK & CO. INC. (US) | 1985-04-17 | — | — | EP | claimed |
| US-4490546-A | Process for 4a'(R),5'-dihydromevinolin | MERCK & CO., INC. (US) | 1984-12-25 | — | — | US | claimed |
| EP-0010299-A1 | Pharmaceutical composition useful for the treatment of hypercholesteremia | MERCK & CO. INC. (US) | 1980-04-30 | — | — | EP | claimed |